Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): equality impact assessment - scoping

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): response to consultee and commentator comments on the draft scope and provisional matrix

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): final matrix

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): final scope

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib): provisional matrix (pre-referral)

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib): draft scope (pre-referral)